Eli Lilly presented encouraging early Phase 1 results for AJ1-11095, a type II JAK2 inhibitor in development for myelofibrosis, at the European Hematology Association meeting. The drug came through Lilly’s acquisition of Ajax Therapeutics, and interim data were framed as supportive of AJ1-11095’s potential role as a next-generation option in a treatment area dominated by JAK inhibitors. Analysts noted the competitive implications, with the potential for AJ1-11095 to challenge Incyte’s Jakafi depending on efficacy, safety, and differentiation versus current standards.